Drug – bio-affecting and body treating compositions – Conjugate or complex of monoclonal or polyclonal antibody,...
Patent
1993-01-15
1996-06-18
Kim, Kay K. A.
Drug, bio-affecting and body treating compositions
Conjugate or complex of monoclonal or polyclonal antibody,...
5303911, 5303917, 530399, A61K 3944, C07K 1448, C07K 1646, C07K 1702
Patent
active
055275273
ABSTRACT:
The present invention pertains to a method for delivering a neuropharmaceutical or diagnostic agent across the blood brain barrier to the brain of a host. The method comprises administering to the host a therapeutically effective amount of an antibody-neuropharmaceutical or diagnostic agent conjugate wherein the antibody is reactive with a transferrin receptor. Other aspects of this invention include a delivery system comprising an antibody reactive with a transferrin receptor linked to a neuropharmaceutical or diagnostic agent and methods for treating hosts afflicted with a disease associated with a neurological disorder.
REFERENCES:
patent: 4292425 (1981-09-01), Buckler et al.
patent: 4434156 (1984-02-01), Trowbridge
patent: 4444744 (1984-04-01), Goldenberg
patent: 4545985 (1985-10-01), Pastan et al.
patent: 4569789 (1986-02-01), Blattler et al.
patent: 4626507 (1986-12-01), Trowbridge et al.
patent: 4631190 (1986-12-01), Shen et al.
patent: 4801575 (1989-01-01), Pardridge
patent: 4886780 (1989-12-01), Faulk
patent: 4892827 (1990-01-01), Pastan et al.
patent: 4902505 (1990-02-01), Pardridge
patent: 4992255 (1991-02-01), Pardridge
patent: 5004697 (1991-04-01), Pardridge
patent: 5087616 (1992-02-01), Meyers et al.
patent: 5108987 (1992-04-01), Faulk
patent: 5130129 (1992-07-01), Pardridge
patent: 5154924 (1992-10-01), Friden
patent: 5182107 (1993-01-01), Friden
Grog et al (1983) Proc. Natl. Acad. sci USA 80:6819-6823.
Batra et al (1989) Proc. Natl. Acad. Sci. USA 86:8545-8549.
Batra et al (1991) Mal. Cellular Biol. 11 (4): 2200-2205.
Jeffries et al (1985) Immunology 54:333-341.
Iunard et al (1990) Exp. Neurology 110:25-38.
Olsoneral (1992) J. Neural Tranan. (P-D Sect) 4:79-95.
Eriksdotter-Nilssoneral (1989) Neuroscience 30 (3):755-66 Kordower et al (1994) Proc. Natl. Acad. Sci USA 91:9077-9080.
Trowbridge, I. S. et al., "Anti-Transferrin Receptor Monoclonal Antibody and Toxin-Antibody Conjugates Affect Growth of Human Tumour Cells", Nature, 294 (12): 171-173 (Nov. 1981).
Domingo, D. L. et al. , "Transferrin Receptor as a Target for Antibody-Drug Conjugates", Methods in Enzymology, 112: 238-247 (1985).
Zovickian, J. et al., "Potent and Specific Killing of Human Malignant Brain Tumor Cells by an Anti-Transferrin Receptor Antibody-Ricin Immunotoxin", J. Neurosurg. , 66: 850-861 (1987).
Jeffries, W. A. et al., "Transferrin Receptor on Endothelium of Brain Capillaries", Nature , 312(8): 162-163 (1984).
Raso, V. et al., "Monensin is Obligatory for the Cytotoxic Action of a Disulfide Linked Methotrexate-Anti-Transferrin Receptor Conjugate", Biochem. Biophy. Res. Comm., 150(1): 104-110 (1988).
Bjorn, M. J. et al., "Immunotoxins to the Murine Transferrin Receptor: Intracavitary Therapy of mice Bearing Syngeneic Peritoneal Tumors" Cancer Research 47 (24, Pt.1): 6639-6645 Dec. 15, 1987).
Smyth, M. J. et al., "The Mode of Action of Methotrexate-Monoclonal Antibody Conjugates" Immunol. Cell. Biol., 65(2): 189-200 (1987).
Pardridge, W. M. "Receptor-Mediated Peptide Transport through the Blood-Brain Barrier", Endocrine Reviews, 7(3): 314-330 (1986).
Sutherland, R. et al., "Ubiquitous Cell-Surface Glycoprotein on Tumor Cells is proliferation-Associated Receptor for Transferrin", Proc. Nat'l Acad. Sci. USA, 78(7): 4515-4519 (Jul. 1981).
Shen, W.-C. et al., "CIS-Aconityl Spacer Between Daunomycin and Macromolecular Carriers: A Model of Ph-Sensitive Linkage Releasing Drug from a Lysosomotropic Conjugate" Biochem. and Biophys. Res. Comm. 2(3): 1048-1054 (Oct. 15, 1981).
Pietersz, G. A. et al., "Novel Synthesis and in vivo Characterization of Disulfide-linked Ricin-Monoclonal Antibody Conjugates Devoid of Galactose Binding Activity" Cancer Res., 48: 4469-4476 (1988).
Pietersz, G. A. et al., "The Use of Monoclonal Antibody Conjugates for the Diagnosis and Treatment of Cancer" Immunol. Cell Biol., 65 (Pt. 2): 111-125 (1987).
Gascoigne, N. R. J. et al., "Secretion of a Chimeric T-Cell Receptor-Immunoglobulin Protein"Proc. Nat'l Acad. Sci. USA 84: 2936-2940 (1987).
Baldwin, R. W. et al., "Monoclonal Antibodies for Radiommunodetection of Tumours and for Targeting" Bull. Cancer (Paris) 70(2): 132-136 (1983).
Byrn, R. A. et al., "Biological Properties of a CD4 Immunoadhesin" Nature 344: 667-670 (1990).
Griffin, T. W. et al., "In Vitro Cytotoxicity of Recombinant Ricin A Chain-Antitransferrin Receptor Immunotoxin Against Human Adenocarcinomas of Colon and Pancreas" J. Biol. Res. Mod., 7: 559-567 (1988).
Alkan, S. S. et al., "Antiviral and Antiproliferative Effects of Interferons Delivered via Monoclonal Antibodies" J. Interferon Res. , 4(3): 355-363 (1984).
Capon, D. J. et al., "Designing CD4 Immunoadhesins for AIDS Therapy" Nature 337: 525-531 (1989).
Dautry-Varsat, A. et al., "pH and the Recycling of Transferrin During Receptor-mediated Endocytosis" Proc. Nat'l Acad. Sci. USA 80; 2258-2262 (Apr. 1983).
Fishman, J. B. et al., "Receptor-Mediated Transcytosis of Transferrin Across the Blood-Brain Barrier" J. Neur. Res., 18: 299-304 (1987).
Pardridge, W. M. et al., "Selective Transport of an Anti-transferrin Receptor Antibody through the Blood-Brain Barrier in vivo" J. Pharmacol. and Exp. Therapeutics 259 (1): 66-70 (1991).
Morrison, S. L. et al., "Genetically Engineered Antibody Molecules: New Tools for Cancer Therapy" Cancer Investigation 6 (2): 185-192 (1988).
Alkermes, Inc.
Kim Kay K. A.
LandOfFree
Transferrin receptor specific antibody-neuropharmaceutical agent does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Transferrin receptor specific antibody-neuropharmaceutical agent, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Transferrin receptor specific antibody-neuropharmaceutical agent will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-221137